Brokerages Set AMAG Pharmaceuticals, Inc. (AMAG) Target Price at $21.64

AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) has earned an average rating of “Hold” from the nineteen brokerages that are currently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and three have assigned a buy rating to the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $21.64.

A number of equities analysts have commented on the company. Zacks Investment Research raised AMAG Pharmaceuticals from a “hold” rating to a “buy” rating and set a $21.00 target price for the company in a report on Wednesday, October 4th. Morgan Stanley started coverage on AMAG Pharmaceuticals in a research report on Friday, September 8th. They issued an “overweight” rating and a $26.00 price target for the company. Cantor Fitzgerald restated a “hold” rating and issued a $21.00 price target on shares of AMAG Pharmaceuticals in a research report on Thursday, September 28th. Janney Montgomery Scott restated a “hold” rating on shares of AMAG Pharmaceuticals in a research report on Tuesday, October 17th. Finally, Piper Jaffray Companies started coverage on AMAG Pharmaceuticals in a research report on Monday, October 23rd. They issued a “neutral” rating and a $18.00 price target for the company.

Shares of AMAG Pharmaceuticals (NASDAQ:AMAG) traded down $0.25 during trading on Tuesday, hitting $14.55. The company’s stock had a trading volume of 619,089 shares, compared to its average volume of 880,250. AMAG Pharmaceuticals has a fifty-two week low of $11.93 and a fifty-two week high of $36.60. The firm has a market capitalization of $513.45, a PE ratio of -2.39 and a beta of 0.79. The company has a quick ratio of 1.48, a current ratio of 1.59 and a debt-to-equity ratio of 0.94.

A number of institutional investors have recently modified their holdings of the stock. State Street Corp grew its position in AMAG Pharmaceuticals by 10.6% in the second quarter. State Street Corp now owns 2,789,932 shares of the specialty pharmaceutical company’s stock worth $51,336,000 after acquiring an additional 267,873 shares during the period. Dimensional Fund Advisors LP grew its position in AMAG Pharmaceuticals by 18.5% in the second quarter. Dimensional Fund Advisors LP now owns 1,215,249 shares of the specialty pharmaceutical company’s stock worth $22,361,000 after acquiring an additional 189,576 shares during the period. Gotham Asset Management LLC grew its position in AMAG Pharmaceuticals by 17.8% in the second quarter. Gotham Asset Management LLC now owns 800,055 shares of the specialty pharmaceutical company’s stock worth $14,721,000 after acquiring an additional 121,137 shares during the period. Renaissance Technologies LLC grew its position in AMAG Pharmaceuticals by 1.7% in the second quarter. Renaissance Technologies LLC now owns 778,800 shares of the specialty pharmaceutical company’s stock worth $14,330,000 after acquiring an additional 12,800 shares during the period. Finally, Prudential Financial Inc. grew its position in AMAG Pharmaceuticals by 35.7% in the third quarter. Prudential Financial Inc. now owns 725,357 shares of the specialty pharmaceutical company’s stock worth $13,382,000 after acquiring an additional 190,660 shares during the period.

ILLEGAL ACTIVITY NOTICE: This article was first reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this article on another website, it was stolen and reposted in violation of United States and international trademark and copyright laws. The correct version of this article can be accessed at https://stocknewstimes.com/2018/01/05/brokerages-set-amag-pharmaceuticals-inc-amag-target-price-at-21-64.html.

AMAG Pharmaceuticals Company Profile

AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.

Analyst Recommendations for AMAG Pharmaceuticals (NASDAQ:AMAG)

Receive News & Ratings for AMAG Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply